Memory Pharmaceuticals, The Stanley Medical Research Institute deal

MEMY received a $640,000 milestone from the institute in January under a 2006 deal to develop MEMY's MEM 1003 to treat acute mania in bipolar disorder. The payment was triggered by MEMY meeting a set ...